BMS feels the pain of Revlimid erosion, cutting forecasts

Bristol-Myers Squibb is facing some serious near-term challenges as its top-selling drugs come under pressure, forcing it to slash its sales forecasts for the year.

BMS' cash cow Revlimid faces first generic rivals in US

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales

NICE reverses stance on Celgene’s Revlimid for myeloma maint...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

Scotland backs two myeloma drugs turned down by NICE in Engl...

A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) backed NHS use of two drugs previously turned down by NICE in England.<

NICE backs Celgene’s Revlimid for chemo-free lymphoma therap...

Celgene bags FDA okay for Revlimid combo in lymphoma

Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use alongside Roche’s Rituxan for two additional forms of indolent non-Hodgkin